Search hospitals > New York > Stony Brook
Stony Brook University Cancer Center
Claim this profileStony Brook, New York 11794
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Leukemia
59 reported clinical trials
4 medical researchers
Summary
Stony Brook University Cancer Center is a medical facility located in Stony Brook, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer, Leukemia and other specialties. Stony Brook University Cancer Center is involved with conducting 59 clinical trials across 70 conditions. There are 4 research doctors associated with this hospital, such as Minsig Choi, Amna Sher, Alexander N. Slade, and Alison Stopeck, MD.Area of expertise
1Breast Cancer
Global LeaderStage III
Stage IV
HER2 negative
2Lung Cancer
Global Leadermetastatic
locally advanced
Stage IV
Top PIs
Minsig ChoiStony Brook Cancer Center5 years of reported clinical research
Studies Colorectal Cancer
Studies Stomach Cancer
10 reported clinical trials
20 drugs studied
Amna SherStony Brook University Medical Center3 years of reported clinical research
Studies Cancer
Studies Lung Cancer
9 reported clinical trials
14 drugs studied
Alexander N. SladeStony Brook University Medical Center2 years of reported clinical research
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
7 reported clinical trials
32 drugs studied
Alison Stopeck, MDStony Brook University Cancer Center3 years of reported clinical research
Studies Breast Cancer
Studies Chemotherapy
5 reported clinical trials
8 drugs studied
Clinical Trials running at Stony Brook University Cancer Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Thyroid Nodule
Thyroid Disease
Sacituzumab Tirumotecan + Pembrolizumab
for Breast Cancer
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.
Recruiting2 awards Phase 33 criteria
DNA-Guided Adjuvant Therapy
for Breast Cancer
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Recruiting1 award Phase 29 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Stony Brook University Cancer Center?
Stony Brook University Cancer Center is a medical facility located in Stony Brook, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Cancer, Leukemia and other specialties. Stony Brook University Cancer Center is involved with conducting 59 clinical trials across 70 conditions. There are 4 research doctors associated with this hospital, such as Minsig Choi, Amna Sher, Alexander N. Slade, and Alison Stopeck, MD.